首页|雷洛昔芬与氯米芬对多囊卵巢综合征合并不孕症患者血清性激素水平、排卵情况的影响对比

雷洛昔芬与氯米芬对多囊卵巢综合征合并不孕症患者血清性激素水平、排卵情况的影响对比

扫码查看
目的 探究多囊卵巢综合征(PCOS)合并不孕症患者予以雷洛昔芬、氯米芬治疗对其排卵情况以及血清性激素水平的影响.方法 100 例PCOS合并不孕症患者,以计算机表法分为对照组和研究组,每组 50 例.对照组给予氯米芬治疗,研究组给予雷洛昔芬治疗.比较两组患者血清性激素[孕酮(P)、雌二醇(E2)、促卵泡生成素(FSH)、黄体生成素(LH)、睾酮(T)]水平、卵泡情况、子宫内膜情况[子宫内膜厚度、子宫内膜螺旋动脉搏动指数(PI)、阻力指数(RI)]、治疗效果、不良反应发生情况.结果 治疗后,研究组患者血清LH水平(9.74±1.36)IU/L高于对照组的(8.42±1.19)IU/L,T水平(1.59±0.48)nmol/L低于对照组的(2.64±0.65)nmol/L,差异有统计学意义(P<0.05).研究组患者成熟卵泡个数(1.41±0.28)个多于对照组的(1.12±0.24)个,卵泡成熟时间(12.85±1.44)d短于对照组的(14.96±1.14)d,差异有统计学意义(P<0.05).研究组患者子宫内膜厚度(9.45±1.25)mm高于对照组的(6.45±1.17)mm,子宫内膜螺旋动脉PI(1.24±0.11)、RI(0.61±0.09)低于对照组的(1.41±0.25)、(0.86±0.07),差异有统计学意义(P<0.05).研究组患者治疗总有效率 96.00%高于对照组的 92.00%,但差异无统计学意义(P>0.05).研究组患者不良反应发生率2.00%低于对照组的14.00%,差异具有统计学意义(P<0.05).结论 相比较氯米芬,雷洛昔芬治疗PCOS合并不孕症患者效果显著,能改善患者血清性激素水平,减少不良反应发生,改善子宫内膜情况,值得广泛使用.
comparison of the impact of raloxifene and clomiphene on serum sex hormone levels and ovulation status of patients with polycystic ovary syndrome and infertility
Objective To explore the impact of raloxifene and clomiphene on serum sex hormone levels and ovulation status of patients with polycystic ovary syndrome(PCOS)and infertility.Methods A total of 100 patients with PCOS and infertility were selected for analysis.They were divided into a control group and a study group by computer table method,,with 50 patients in each group.The control group was treated with clomiphene,and the study group was treated with raloxifene.Patients in both groups were compared in terms of serum sex hormones[progesterone(P),estradiol(E2),follicle stimulating hormone(FSH),luteinizing hormone(LH),testosterone(T)]levels,follicular and endometrial conditions[endometrial thickness,endometrial spiral artery pulsatility index(PI),resistance index(RI)],treatment effects,and adverse reactions.Results After treatment,the study group had higher serum LH level of(9.74±1.36)IU/L than(8.42±1.19)IU/L in the control group,and lower T level of(1.59±0.48)nmol/L than(2.64±0.65)nmol/L in the control group.The difference was statistically significant(P<0.05).The study group had higher number of mature follicles of(1.41±0.28)than(1.12±0.24)in the control group,and shorter time of follicle maturation of(12.85±1.44)d than(14.96±1.14)d in the control group.The difference was statistically significant(P<0.05).The study group had higher endometrial thickness of(9.45±1.25)mm than(6.45±1.17)mm in the control group;the study group had endometrial spiral artery PI of(1.24±0.11)and RI of(0.61±0.09),which were lower than(1.41±0.25)and(0.86±0.07)in the control group;the difference was statistically significant(P<0.05).The total effective rate of the study group was 96.00%,which was higher than 92.00%in the control group,but the difference was not statistically significant(P>0.05).The incidence of adverse reactions in the study group was 2.00%,which was lower than 14.00%in the control group,and the difference was statistically significant(P<0.05).Conclusion Compared with clomiphene,raloxifene has a significant effect on the treatment of PCOS with infertility.It can improve serum sex hormone levels,reduce adverse reactions,and improve the condition of the endometrium in patients.It is worthy of widespread use.

Polycystic ovary syndromeInfertilityRaloxifeneClomipheneSex hormonesOvulation

李秀玲

展开 >

252600 临清市人民医院

多囊卵巢综合征 不孕症 雷洛昔芬 氯米芬 性激素 排卵

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(12)